title: Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia.
abstract: OBJECTIVE
  Despite the established role of imatinib (IM) in chronic myelogenous leukemia (CML) in adults, there are few reports on its efficacy in children. In this study, we compared the outcomes of children with CML before and after the advent of IM-based treatment.
  
  
  METHODS
  The study cohort consisted of 52 patients treated for CML at the Department of Pediatrics, The Catholic University of Korea from January 1995 to October 2010. Patients were divided and analyzed according to the preImatinib group (pre-IMG) and imatinib group (IMG).
  
  
  RESULTS
  Median age at diagnosis for the overall cohort (pre-IMG, n=27; IMG, n=25) was 9 years, with a median follow-up duration of survivors of 84 months. Except for 5 patients in the IMG, all were diagnosed in chronic phase (CP). The overall survival (OS) of patients diagnosed in CP was 45.7% and 89.7% for pre-IMG and IMG, respectively (P=0.025). The OS of hematopoietic stem cell transplantation (HSCT) recipients in the 2 groups was similar, but the OS of patients diagnosed in CP who did not receive HSCT was superior in IMG (91.7% vs. 16.7%, P=0.014). Of the 12 patients in IMG who remained on IM without HSCT, 2 showed disease progression, compared to 11 of 12 in pre-IMG. No difference was observed in the progression free survival (PFS) of matched donor HSCT recipients and IM-based treatment recipients.
  
  
  CONCLUSIONS
  Similar PFS of patients treated with IM and those who received matched donor HSCT underscore the potential of IM as effective first-line treatment in childhood CML.
authors.affiliation: Department of Pediatrics, The Catholic University of Korea College of Medicine, Seoul, Korea.
authors.forename: Hyun Jin
authors.initials: HJ
authors.lastname: Oh
authors.forename: Mun Sung
authors.initials: MS
authors.lastname: Cho
authors.forename: Jae Wook
authors.initials: JW
authors.lastname: Lee
authors.forename: Pil-Sang
authors.initials: PS
authors.lastname: Jang
authors.forename: Nack-Gyun
authors.initials: NG
authors.lastname: Chung
authors.forename: Bin
authors.initials: B
authors.lastname: Cho
authors.forename: Hack-Ki
authors.initials: HK
authors.lastname: Kim
keywords: Allogeneic transplantation; Children; Chronic myelogenous leukemia; Imatinib mesylate
references.citation: Biol Blood Marrow Transplant. 2010 May;16(5):639-46
references.pmid: 20005967
references.citation: Blood. 2012 Feb 23;119(8):1821-30
references.pmid: 22210880
references.citation: Blood. 2003 Aug 15;102(4):1224-31
references.pmid: 12714525
references.citation: Korean J Pediatr. 2011 Mar;54(3):111-6
references.pmid: 21738540
references.citation: Pediatr Clin North Am. 1988 Aug;35(4):765-87
references.pmid: 3047653
references.citation: Blood. 2007 Apr 15;109(8):3496-9
references.pmid: 17192396
references.citation: Lancet Oncol. 2010 Nov;11(11):1029-35
references.pmid: 20965785
references.citation: Bone Marrow Transplant. 2003 Nov;32(10):993-9
references.pmid: 14595387
references.citation: Blood. 1999 Sep 1;94(5):1517-36
references.pmid: 10477676
references.citation: N Engl J Med. 1999 Apr 29;340(17):1330-40
references.pmid: 10219069
references.citation: Leukemia. 2009 Jun;23(6):1054-61
references.pmid: 19282833
references.citation: J Clin Oncol. 2011 Mar 1;29(7):839-44
references.pmid: 21263099
references.citation: Hematol Oncol. 2012 Dec;30(4):200-5
references.pmid: 22241698
references.citation: N Engl J Med. 2006 Dec 7;355(23):2408-17
references.pmid: 17151364
references.citation: Pediatr Blood Cancer. 2012 Sep;59(3):481-4
references.pmid: 22052850
references.citation: Lancet Oncol. 2011 Sep;12(9):841-51
references.pmid: 21856226
references.citation: Int J Hematol. 2011 Feb;93(2):186-191
references.pmid: 21234820
references.citation: Leukemia. 2006 Feb;20(2):187-92
references.pmid: 16341042
references.citation: J Clin Oncol. 2009 Dec 10;27(35):6041-51
references.pmid: 19884523
references.citation: J Pediatr. 2011 Oct;159(4):676-81
references.pmid: 21592517
references.citation: Leuk Lymphoma. 2012 Dec;53(12):2430-3
references.pmid: 22607062
references.citation: Clin Cancer Res. 2004 Aug 1;10(15):5065-71
references.pmid: 15297408
references.citation: J Clin Oncol. 2011 Jul 10;29(20):2827-32
references.pmid: 21670449
references.citation: Blood. 2008 Apr 15;111(8):4022-8
references.pmid: 18256322
references.citation: Blood. 2012 Feb 2;119(5):1123-9
references.pmid: 22160483